Indanylacetic acids as PPAR-δ activator insulin sensitizers

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 15, 2007, Pages 4369-4373

  Wickens, Philip ^a   Zhang, Chengzhi ^a   Ma, Xin ^a   Zhao, Qian ^a   Amatruda, John ^a   Bullock, William ^a   Burns, Michael ^a   Cantin, Louis David ^a   Chuang, Chih Yuan ^a   Claus, Thomas ^a   Dai, Miao ^a   Dela Cruz, Fernando ^a   Dickson, David ^a   Ehrgott, Frederick J ^a   Fan, Dongping ^a   Heald, Sarah ^a   Hentemann, Martin ^a   Iwuagwu, Christiana I ^a   Johnson, Jeffrey S ^a   Kumarasinghe, Ellalahewage ^a   Ladner, David ^a   Lavoie, Rico ^a   Liang, Sidney ^a   Livingston, James N ^a   Lowe, Derek ^a   Magnuson, Steve ^a   Mannelly, Gretchen ^a   Mugge, Ingo ^a   Ogutu, Herbert ^a   Pleasic Williams, Susan ^a   Schoenleber, Robert W ^a   Shapiro, Jeff ^a   Shelekhin, Tatiana ^a   Sweet, Laurel ^a   Town, Christopher ^a   Tsutsumi, Manami ^a   more..

^a BAYER CORPORATION   (United States)

Author keywords

Indane acetic acids; Insulin sensitizer; PPAR

Indexed keywords

ACETIC ACID DERIVATIVE; INDAN DERIVATIVE; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ARTICLE; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; IN VIVO STUDY; NONHUMAN; SUSTAINED RELEASE PREPARATION;

FLUORESCENCE RESONANCE ENERGY TRANSFER; INSULIN RESISTANCE; PPAR DELTA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34347387498     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.057     Document Type: Article

References (19)

1. Savkur R.S., and Miller A.R. Expert Opin. Investig. Drugs 15 (2006) 763
2. Ramachandran U., Kumar R., and Mittal A. Mini Rev. Med. Chem. 6 (2006) 563
3. Hummasti S., and Tontonoz P. Mol. Endocrinol. 20 (2006) 1261
4. Semple R.K., Krishna K., Chatterjee K., and O'Rahilly S. J. Clin. Invest. 116 (2006) 581
5. Ram V.J. Drugs Today 39 (2003) 609
6. Henke B.R. J. Med. Chem. 47 (2004) 4118
7. Lowe D.B., Bifulco N., Bullock W.H., Claus T., Coish P., Dai M., Dela Cruz F.E., Dickson D., Fan D., Hoover-Litty H., Li T., Ma X., Mannelly G., Monahan M., Muegge I., O'Connor S., Rodriguez M., Shelekin T., Stolle A., Sweet L., Wang M., Wang Y., Zhang C., Zhang H., Zhang M., Zhao K., Zhao Q., Zhu J., Zhu L., and Tsutsumi M. Biorg. Med. Chem. Lett. 16 (2006) 297
8. Barish G.D., Nakar V.A., and Eveans R.M. J. Clin. Invest. 116 (2006) 590
9. Bedu E., Wahli W., and Desvergne B. Expert Opin. Ther. Targets 9 (2005) 861
10. Evans J.L., Lin J.J., and Goldfine I.D. Curr. Diab. Rev. 1 (2005) 299
11. Cantin, L.-D.; Liang, S.; Ogutu, H.; Iwuagwu, C. I.; Boakye, K.; Bullock, W.; Burns, M.; Clark, R.; Claus, T.; delaCruz, F. E.; Daly, M.; Ehrgott, F. J.; Johnson, J. S.; Keiper, C.; Livingston, J. N.; Schoenleber, R. W.; Shapiro, J.; Town, C.; Yang, L.; Tsutsumi, M.; Ma, X. Biorg. Med. Chem. Lett. 2007, in Press.
12. Liu K.G., Lambert M.H., Leesnitzer L.M., Oliver W.J., Ott R.J., Plunket K.D., Stuart L.W., Brown P.J., Wilson T.M., and Sternbach D.D. Biorg. Med. Chem. Lett. 11 (2001) 2959
13. Xu Y., Etgen G.J., Broderick C.L., Canada E., Gonzalez I., Lamar J., Montrose-Rafizadeh C., Oldham B.A., Osborne J.J., Xie C., Shi Q., Winneroski L.L., York J., Yumibe N., Zink R., and Mantlo N. J. Med. Chem. 49 (2006) 5649
14. Lowe, D. B.; Wickens, P. L.; Ma, X.; Zhang, M.; Bullock, W. H.; Coish, P. D. G.; Mugge, I. A.; Stolle, A.; Wang, M.; Wang, Y.; Zhang, C.; Zhang, H.; Zhu, L.; Tustsumi, M.; Livingston, J. WO 03/011842.
15. Wickens, P. L.; Cantin, L.; Chuang, C.; Dai, M.; Hentemann, M. F.; Kumarasinghe, E.; Liang, S. X.; Lowe, D. B.; Shelekhin, T. E.; Wang, Y.; Zhang, C.; Zhang, H.; Zhao, Q. WO 2004/011446.
16. Wickens, P. L.; Cantin, L.; Kumarasinghe, E.; Chuang, C.; Liang, S. X. WO 2003/089418.
17. BAY compounds were incubated with europium-labeled anti-GST antibody, GST-tagged human PPAR-δ ligand binding domain, biotinylated TRAP220 coactivator protein, and streptavidin-labeled APC. The samples were placed in a fluorimeter with an excitation wavelength of 340 nm and emission wavelengths of 615 and 665 nm.
18. 50 value was determined if a plateau was attained and percent maximum stimulation was assessed.
19. Chiral HPLC method: chiralpak AD-H 4.6 × 250 mm. A = hexane (0.4% TFA) B = IPA. 10% B at 1 mL/min. UV = 280 nM.